|Hospital:||The University of Texas M.D. Anderson Cancer Center|
|Patients: This Phase II study involved 24 patients with malignant pleural mesothelioma|
Treatment: The treatment consisted of the administration of the drug Doxil.
Toxicity: Toxicities included cardiac, mild elevations of alkaline phosphatase, nausea, and hematological. One patient had a grade 4 neutropenia.
Results: No objective responses were observed and the overall median survival was 37 weeks (8.5 months).
Support: The study was supported in part by Sequus Pharmaceuticals, Inc. Sequus manufactures Doxil.
Correspondence: Dong M. Shin, MD